Background-Inflammation and pericarditis may be contributing factors for postoperative atrial fibrillation (POAF), and both are potentially affected by antiinflammatory drugs and colchicine, which has been shown to be safe and efficacious for the prevention of pericarditis and the postpericardiotomy syndrome (PPS). The aim of the Colchicine for the Prevention of the Post-Pericardiotomy Syndrome (COPPS) POAF substudy was to test the efficacy and safety of colchicine for the prevention of POAF after cardiac surgery. Methods and Results-The COPPS POAF substudy included 336 patients (mean age, 65.7Ϯ12.3 years; 69% male) of the COPPS trial, a multicenter, double-blind, randomized trial. Substudy patients were in sinus rhythm before starting the intervention (placebo/colchicine 1.0 mg twice daily starting on postoperative day 3 followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients Ն70 kg, halved doses for patients Ͻ70 kg or intolerant to the highest dose). The substudy primary end point was the incidence of POAF on intervention at 1 month. Despite well-balanced baseline characteristics, patients on colchicine had a reduced incidence of POAF (12.0% versus 22.0%, respectively; Pϭ0.021; relative risk reduction, 45%; number needed to treat, 11) with a shorter in-hospital stay (9.4Ϯ3.7 versus 10.3Ϯ4.3 days; Pϭ0.040) and rehabilitation stay (12.1Ϯ6.1 versus 13.9Ϯ6.5 days; Pϭ0.009). Side effects were similar in the study groups. Conclusion-Colchicine seems safe and efficacious in the reduction of POAF with the potentiality of halving the complication and reducing the hospital stay. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00128427.
mon and troublesome, affecting 10% to 40% of patients after cardiac surgery. [11] [12] [13] [14] Because of its antiinflammatory effect, colchicine may also reduce the risk of POAF. A substudy of the COPPS trial was designed to evaluate the efficacy of colchicine in preventing POAF. This is the first study to test the hypothesis that colchicine may prevent POAF.
Methods

Trial Design and Participants
This was a prospective, randomized, double-blind, placebocontrolled, multicenter trial. The overall study population consisted of 360 patients enrolled at 6 hospitals in Italy (Maria Vittoria Hospital, Torino; Ospedali Riuniti, Bergamo; Mauriziano Hospital, Torino; Niguarda Hospital, Milano; San Maurizio Regional Hospital, Bolzano; and Ospedale degli Infermi, Rivoli).
Inclusion Criteria
All consecutive adult patients undergoing cardiac surgery and without contraindications to colchicine were recruited. Eligible patients had no unfavorable short-term outlook and were willing and able to give informed consent and to comply with the study procedures and follow-up. For the COPPS POAF substudy, all patients in sinus rhythm on day 3 were included for the analysis of colchicine effects (either stable sinus rhythm or intermittent POAF but in sinus rhythm on day 3 at the time of colchicine/placebo administration). Thus, the COPPS POAF substudy population included 336 patients (Figure 1 ).
Exclusion Criteria
The study exclusion criteria included (1) known severe liver disease or current transaminases Ͼ1.5 times the upper normal limit, (2) current serum creatinine Ͼ2.5 mg/dL, (3) known myopathy or elevated baseline preoperative creatine kinase, (4) known blood dyscrasias or gastrointestinal disease, (5) pregnant and lactating women or women of childbearing potential not protected by a contraception method, (6) known hypersensitivity to colchicine, and (7) current treatment with colchicine for any indications. For the COPPS POAF substudy, POAF events limited to days 1 and 2 were excluded from the analysis because the effect of colchicine could not be evaluated (the drug was administered starting on day 3). The protocol excluded patients with chronic AF and those with persistent POAF on day 3 before starting colchicine.
Interventions
Patients were randomized to receive placebo or colchicine on top of standard therapy. Treatment with placebo or colchicine started on postoperative day 3. Colchicine was given at the dosage of 1.0 mg twice daily for the first day followed by a maintenance dosage of 0.5 mg twice daily for 1 month in patients Ն70 kg, and halved doses were given to patients Ͻ70 kg or intolerant to the highest dose. The rhythm was defined as AF when there were no consistent P waves before each QRS complex and the ventricular rate was irregular. AF episodes lasting Ͼ5 minutes were considered. Recognition of AF was performed by continuous ECG monitoring (3-channel ward monitor) and 12-lead ECG recordings.
End Points
The COPPS POAF substudy primary end point was the rate of POAF on placebo/colchicine treatment. Additional analyses included hospital stay (cardiac surgery, rehabilitation, overall stay) and the incidence of death and stroke.
Randomization
Participants were randomly assigned to treatments by a central computer-based, automated sequence based on permuted blocks with a block size of 4. The random allocation sequence was implemented by sequentially numbered containers. All participants and trial investigators were blinded to randomized treatment. Tablets identical in color, shape, and taste were provided in blister packs. Data were collected on case report forms and clinical events adjudication forms. Data were managed by investigators blinded to treatment assignments. A blinded clinical end point committee adjudicated all events. 
Safety
During follow-up, monitoring and recording of all adverse events were performed. Potential side effects to be monitored included gastrointestinal effects (especially diarrhea), alopecia, anorexia, hepatotoxicity, myotoxicity, and bone marrow toxicity. An untoward event that was fatal or life-threatening, required hospitalization, or was significantly or permanently disabling or medically significant (may jeopardize the patient and may require medical or surgical intervention to prevent an adverse outcome) was recorded as a severe adverse event.
Statistical Analysis and Sample Size
For the COPPS POAF substudy, a total of 250 patients, 125 in each treatment arm, were needed to detect a difference in the POAF rate of 48.0% and 30.0% between the 2 treatment arms (placebo and colchicine) with a power of 80% using a 2-sided Pϭ0.05 level test. The estimated rates of the POAF in the 2 study groups were based on the results of a randomized controlled trial in which the incidence of POAF was significantly lower in the hydrocortisone group (30%) than in the placebo group (48%; adjusted hazard ratio, 0.54; 95% confidence interval, 0.35-0.83; Pϭ0.004). 15 Analyses were performed by intention to treat. For the COPPS POAF substudy, intention-to-treat analysis was applied to patients enrolled in the substudy (336 patients) from the original overall study population of the COPPS trial (360 patients).
Data are expressed as meanϮSD. Comparisons between patient groups were performed with the Mann-Whitney test for continuous variables and a 2 analysis for categorical variables. A value of PϽ0.05 was considered to show statistical significance. Time-to-event distributions were estimated by the Kaplan-Meier method and compared with the log-rank test. The Cox proportional hazards model was used to identify independent risk factors for recurrences. Stepwise selection procedure was adopted. A value of PϽ0.05 was considered significant for variable entry for stepwise selection. Analyses were performed with the SPSS 13.0 software package (SPSS, Inc, Chicago, IL).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Baseline Characteristics
Baseline patient characteristics were similar between the 2 study groups and are reported in Table 1 . A detailed flow diagram of the study is given in Figure 1 .
Main Outcome
Chronic preoperative AF was recorded in 17 of 360 patients (4.7%). The overall incidence of POAF was 97 of 343 (28.3%): 42 of 97 (43.3%) on postoperative days 1 and 2 (before starting placebo/colchicine) and 55 of 97 (56.7%) from postoperative day 3 (on intervention). Persistent POAF starting on postoperative day 1 or 2 was recorded in 7 patients on postoperative day 3 before randomization to placebo/colchicine. These patients were excluded from subsequent analysis, including a total of 336 patients in sinus rhythm (Figure 1 ). For the assessment of the primary outcome (POAF on placebo or colchicine treatment), only AF events from postoperative day 3, ie, when placebo/ colchicine was administered, were considered. Patients on colchicine had a reduced incidence of POAF (12.0% versus 22.0%, respectively; Pϭ0.021; relative risk reduction, 45%; number needed to treat, 11; Table 2 and Figure 2 ). The POAF events after the start of the intervention (placebo/colchicine) numbered 35 of 167 versus 20 of 169, respectively. The duration of POAF was shorter in the colchicine group compared with the placebo group (3.0Ϯ1.2 versus 7.7Ϯ2.5 days, respectively; PϽ0.001).
Patients treated with colchicine had a shorter in-hospital stay (9.4Ϯ3.7 versus 10.3Ϯ4.3 days; Pϭ0.040), rehabilitation stay (12.1Ϯ6.1 versus 13.9Ϯ6.5 days; Pϭ0.009), and overall hospital stay (cardiac surgery plus rehabilitation stay; 21 versus 24 days, respectively; Pϭ0.030). The incidence of death and stroke was similar in the study groups ( Table 2 ).
The following clinical features were more commonly recorded in patients with POAF on placebo/colchicine treatment compared with those without POAF ( 
Safety and Side Effects
The rates of side effects and drug withdrawal were similar in the colchicine and placebo groups (9.5% versus 4.8%, respectively [Pϭ0.137], for side effects, and 11.8% versus 6.6% [Pϭ0.131] for drug withdrawal), although colchicine showed a trend toward an increased rate of both events. No severe side effects were recorded.
Gastrointestinal intolerance was the only side effect recorded during the study in colchicine-treated patients. One case of myotoxicity was recorded in the placebo group and was related to concomitant use of a statin.
Colchicine was discontinued in 20 patients (11.8%). Patient or medical decision was the cause of drug withdrawal in 2.4% in the colchicine group and 1.8% in the placebo group (Table 5 ).
Discussion
The COPPS POAF substudy was designed to assess the efficacy and safety of colchicine for the prevention of POAF. Colchicine has been shown to be safe and effective in the prevention of pericarditis. 10,16 -20 In the COPPS trial, colchicine halved the incidence of the PPS, providing evidence that pharmacological prevention of the PSS is possible and safe. 10 In the COPPS POAF substudy, colchicine reduced the incidence of POAF (relative risk reduction, 45%; number needed to treat, 11) without significant side effects. Moreover, colchicine halved the mean duration of POAF; such an effect may be particularly important for reducing the subsequence rate of late AF (AF Ͼ30 days of surgery) because a longer duration of POAF is a strong and independent predictor of late AF. 21 The mechanism of POAF is believed to be reentry. The electrophysiological substrate may be preexisting or may develop as a result of heterogeneity of refractoriness after surgery. Multiple perioperative factors have been proposed to contribute to the latter, including operative trauma, inflammation, eleva- POAF indicates postoperative atrial fibrillation; AF, atrial fibrillation; HF, heart failure; COPD, chronic obstructive pulmonary disease; LA, left atrial; CABG, coronary artery by-pass grafting; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin II receptor blocker.
*Excluding pharmacological cardioversion of postoperative atrial fibrillation. The presented variables were determined with a stepwise selection procedure from variables included in Table 3 . A value of PϽ0.05 was considered the significance level for variable entry. tions in atrial pressure (including that resulting from left ventricular diastolic dysfunction), autonomic nervous system imbalance, metabolic and electrolyte imbalances, or myocardial ischemic damage incurred during the operation. 1, 3, 22 Nevertheless, the exact electrophysiological mechanisms causing POAF are incompletely understood. POAF is probably initiated by triggers in patients with a susceptible underlying substrate. Pericardial inflammation, combined with autonomic imbalance, excessive catecholamines production, and hemodynamic factors, may be a significant factor. Both systemic and local inflammatory responses are believed to contribute to the pathogenesis of POAF. Inflammation, inhomogeneity of atrial conduction, and the incidence of POAF are decreased by corticosteroids. 8, 9 On this basis, colchicine may have the potential to be efficacious in preventing not only PPS but also POAF.
In the COPPS POAF substudy, no severe side effects were documented, and gastrointestinal side effects were distributed equally between the colchicine and placebo groups, although colchicine showed a trend toward an increased rate of such complications, as in the main study (Table 5) .
Colchicine is rapidly absorbed from the gastrointestinal tract. Peak concentrations occur in 0.5 to 2 hours. The drug and its metabolites are distributed in leukocytes, kidneys, liver, spleen, and the intestinal tract. The plasma half-life is Ϸ20 minutes, whereas the half-life in leukocytes is Ϸ60 hours. Colchicine is metabolized in the liver and excreted primarily in the feces, with 10% to 20% eliminated unchanged in the urine.
The exact mechanism of colchicine action is not fully understood, but it seems related to its capacity to disrupt microtubules. 19, 23 Colchicine inhibits the process of microtubule self-assembly by binding ␤-tubulin with the formation of tubulin-colchicine complexes. This action takes place either in the mitotic spindle or in the interphase stage; thus, colchicine inhibits the movement of intercellular granules and the secretion of various substances. By this mechanism, colchicine is able to inhibit various leukocytes functions, and this effect should be the most significant for the antiinflammatory action.
It is especially relevant for the antiinflammatory effect and its capability to concentrate in leukocytes, where its peak concentration may be Ͼ10 times the peak concentration in plasma. 19, 23 
Study Limitations
Although the results are encouraging, important issues need to be considered. The relatively small sample size is the first study limitation. This study shows the first evidence of colchicine efficacy for the prevention of POAF, requiring further confirmation and validation in multicenter studies. Moreover, the highest incidence of POAF is generally seen in the first postoperative days. In the COPPS trial, colchicine was given starting on the postoperative day 3 following a preliminary positive experience from Israel. 14 On this basis, the potential beneficial effect of the drug is limited from postoperative day 3, with the potential to miss early postoperative AF cases in the first 2 days. Further research should address whether alternative regimens providing the drug in the perioperative period (eg, starting the administration before the operation) may provide better prevention for either PPS or POAF. Both efficacy and safety should be evaluated in this setting.
Conclusions
Colchicine seems safe and efficacious in reducing the incidence of POAF after cardiac surgery. Such findings may be particularly important for clinical practice because colchicine might represent a cheap and relatively safe option for the prevention of both PPS and POAF, 2 common and troublesome complications of cardiac surgery that may increase management costs. 10, 24, 25 
Sources of Funding
The trial is an independent study founded and performed within the Italian National Healthcare System. The research protocol was approved by the relevant institutional review boards or ethics committees, and all human participants gave written informed consent. The steering committee designed and oversaw the trial and had the final decision on the contents of the manuscript. All data were received, checked, and analyzed independently at the Coordinating Centre at the Cardiology Department, Maria Vittoria Hospital, Torino, Italy, after blinded adjudication of clinical events and side effects. Acarpia Lda supplied of drug/placebo as an unrestricted grant. 
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